Patient characteristics
| Patient no. . | Pathology . | Prior treatment . | Rituximab response . |
|---|---|---|---|
| 1 | Follicular, grade 2 | None | CR |
| 2 | Follicular, grade 1 | Rituximab, GM-CSF–Id-KLH vaccine* | PR |
| 3 | Follicular, grade 3 | DLBCL treated with R-CHOP at 6 cycles and APBSCT relapsed with follicular, grade 3, treated with IFXRT | PD |
| 4 | Follicular, grade 1 | None | PR |
| 5 | Follicular, grade 1 | None | PR |
| Patient no. . | Pathology . | Prior treatment . | Rituximab response . |
|---|---|---|---|
| 1 | Follicular, grade 2 | None | CR |
| 2 | Follicular, grade 1 | Rituximab, GM-CSF–Id-KLH vaccine* | PR |
| 3 | Follicular, grade 3 | DLBCL treated with R-CHOP at 6 cycles and APBSCT relapsed with follicular, grade 3, treated with IFXRT | PD |
| 4 | Follicular, grade 1 | None | PR |
| 5 | Follicular, grade 1 | None | PR |
GM-CSF indicates granulocyte-macrophage colony-stimulating factor; Id-KLH, idiotype–keyhole limpet hemocyanin; DLBCL, diffuse large B-cell lymphoma; R-CHOP, rituximab, cyclophosphamide, adriamycin, vincristine, prednisone; APBSCT, autologous peripheral blood stem cell transplantation; IFXRT, involved field radiation therapy; CR, complete response; PR, partial response; and PD, progressive disease.
At the time of relapse and rituximab retreatment, a new dominant clone, using a different Id (Id′) than that used for the Id vaccine, emerged. This new Id (Id′) was used in the current study.